Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy

Urology. 2007 Jul;70(1):65-8. doi: 10.1016/j.urology.2007.03.024.

Abstract

Objectives: To determine the influence of age on the outcomes of high-risk superficial bladder cancer treated with intravesical bacille Calmette-Guérin (BCG) therapy.

Methods: A total of 805 patients with multiple or recurrent high-grade Ta, T1, and/or carcinoma in situ bladder cancer received BCG therapy. The endpoints were the initial response to BCG and cancer-free survival correlated with age among patients followed up for a minimum of 2 to 5 years.

Results: No difference was observed in the first response to BCG or cancer-free survival at 2 years among patients less than 50, 50 to 59, 60 to 69, 70 to 79, or 80 years or older. After 5 years, 27% of patients older than 70 years were cancer free compared with 37% younger than 70 years (P = 0.005).

Conclusions: The results of our study have shown that aging has a measurable, but small, impact on the overall outcomes of high-risk superficial bladder cancer.

MeSH terms

  • Adjuvants, Immunologic / therapeutic use*
  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • BCG Vaccine / therapeutic use*
  • Carcinoma in Situ / drug therapy*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Risk Factors
  • Treatment Outcome
  • Urinary Bladder Neoplasms / drug therapy*

Substances

  • Adjuvants, Immunologic
  • BCG Vaccine